George Arida has a proven track record of identifying emerging healthcare companies and guiding growth, business strategy, and financial decisions to help create exciting exit opportunities. He joined Venture Investors in 2000 and was appointed Managing Director of the General Partner of Venture Investors Early Stage Fund IV in 2006. Prior to joining Venture Investors, he was the CFO of a financial consulting and brokerage firm.
Mr. Arida served as Chairman of the Board of Directors of Nerites, Inc.through the January 2011 acquisition by Kensey Nash and served as Chairman of Zystor Therapeutics, Inc. He currently serves as Chairman of the Board of Directors of Celleration, Inc. He also serves on the Board of Directors for Chromatin, Inc., ProCertus BioPharm, Inc., and the Mid-America Healthcare Investors Network. He serves as a guest lecturer at the University of Chicago Booth School of Business and the University of Wisconsin School of Business.
Mr. Arida holds a Bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration degree with high honors from the University of Chicago.
James R. Baker, Jr., M.D.
Dr. James Baker is a founder of NanoBio Corporation, and is currently director of the University of Michigan Food Allergy Center. He also is the Ruth Dow Doan Professor of Biologic Nanotechnology, professor emeritus of internal medicine in the Medical School, and biological engineering in the College of Engineering at the University of Michigan.
In 1998, Dr. Baker was appointed director of the new Center for Biologic Nanotechnology, and in 2001 he was inaugurated as the first recipient of the Doan Professorship. Following the success of the Center for Biologic Nanotechnology, in 2005 the U-M Board of Regents formed the Michigan Nanotechnology Institute for Medicine and Biological Sciences and appointed Dr. Baker as its first director. His recent accolades include the Distinguished University Innovator Award from the U-M Office of the Vice President for Research.
Dr. Baker is a medical graduate of the Loyola-Stritch School of Medicine. His research is in the area of immunology and host defense, evolving into nanomaterials, and their applications in medicine. Recently, he has been involved in gene transfer and drug delivery. These studies have produced new vector systems for gene transfer using dendritic polymers, which have the potential to revolutionize pharmaceutical therapy.
Dr. Baker’s work with synthetic lipid and polymeric nanostructures has resulted in the development of nanoemulsions as a new class of antimicrobial agents with activity against bacteria, spores, fungi, and viruses.
Hugo Braun has been an active venture capital investor in the Midwest and California since 1987 and is a cofounder and director of North Coast Technology Investors. Mr. Braun evaluates hundreds of investment opportunities per year, has acted as lead investor in both equity and subordinated debt investments, and has served on the boards of directors of public and private companies.
Prior to founding North Coast, Mr. Braun was a partner in Access Ventures, a Michigan based investment firm with over $30 million under management. In addition, he has co-managed BankAmerica Venture Capital’s $100 million venture portfolio. Investments included computer hardware and software, semiconductors, medical devices, telecommunications and retail. Mr. Braun was also a management consultant with Strategic Planning Associates, a spin-off of the Boston Consulting Group based in Washington, DC. While at SPA, he assisted Fortune 500 clients in the beverage, apparel, petroleum and chemical industries with corporate and financial strategies.
He received an M.S. in Management from the Sloan School of Management at MIT in 1985. He graduated magna cum laude with distinction from Yale University in 1980 with a B.A. in Economics.
Gary E. Costley, Ph.D.
Gary E. Costley, Ph.D., is co-founder and managing director of C&G Capital and Management, LLC, which provides capital and executive management support to health, nutritional, and medical product companies. Previously, he served as Chairman and Chief Executive Officer of International Multifoods Corporation, a manufacturer and marketer of branded consumer food and food service products.
Earlier in his career, Dr. Costley served in numerous executive management positions at Kellogg Company, including most recently as President of Kellogg North America. He currently also serves on the Board of Directors for Covance Inc., The Principal Financial Group, Tiffany & Co., and Prestige Brand Holdings, Inc.
David Peralta has served as Chief Executive Officer of NanoBio Corporation since July 2012. He joined NanoBio in February 2006, and served as Chief Operating and Financial Officer from 2006 through June 2012. During this time, he was directly responsible for all of the company’s business development, fundraising, and finance-related activities, in addition to managing the company’s day-to-day operations.
Prior to joining NanoBio, Mr. Peralta served as Vice President and Chief Financial Officer for Arbortext, Inc., a venture-backed enterprise software company. While at Arbortext, he played a key role in transforming the company to a high-growth software business, which ultimately led to Arbortext being acquired in 2005 for $195 million in cash.
Before joining Arbortext, Mr. Peralta served for six years as the Chief Financial Officer of Mechanical Dynamics, Inc. (NASDAQ: MDII), a publicly-held software company. He directed all finance and investor relations activities at Mechanical Dynamics during the company’s initial public offering in 1996, and up through the sale of the company in 2002. He is a Certified Public Accountant in the State of Michigan.
David M. Stout
David M. Stout has served as a top-level pharmaceutical executive, both nationally and internationally, for the past 30 years. His most recent position was President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals. In this capacity, he led all global commercial activities, global manufacturing, and all vaccine-related activities for the company, including research and development. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program – an international effort that supports governments, health authorities, and company employees around the world in responding to a global influenza pandemic.
Prior to his tenure at GSK, Mr. Stout served as President of SmithKline Beecham’s North American pharmaceutical business, launching two major products and two sales force expansions. His pharmaceutical career began at Warner-Lambert Pharmaceutical Company and continued at Schering-Plough Corporation, where he served in numerous positions, including President of Schering Laboratories.